EGFR mutation (T790M) and cancerous stemness have shown drug resistances in human non-small-cell lung cancer (NSCLC), thus development of novel drugs in overcoming drug resistances in the NSCLC therapy is highly desired. SP101 is a novel gefitinib derivative, which can bind the ATP-binding pocket of EGFR to inhibit its EGFR kinase activity. SP101 can reduce the drug resistances of EGFR mutation (T790M) and cancerous stemness in NSCLC. SP101 induced cancer cell death and apoptosis in the gefitinib-resistant EGFR mutation (T790M) H1975 cells. SP101 inhibited phosphorylated EGFR and its downstream Survivin proteins but conversely induced Caspase 3 activation for apoptosis induction. Moreover, SP101 could decrease Oct4 protein level and reduce Survivin proteins but conversely elicited active Caspase 3 in the xenograft human H1975 lung tumors in nude mice.
EGFR突变(T790M)和癌干细胞特性已经显示出对人非小细胞肺癌(NSCLC)药物的耐药性,因此开发新药物以克服NSCLC治疗中的药物耐药性是非常期望的。
SP101是一种新型
吉非替尼衍
生物,它可以结合
EGFR的
ATP结合口袋,抑制其
EGFR激酶活性。
SP101可以减少NSCLC中
EGFR突变(T790M)和癌干细胞特性的药物耐药性。
SP101诱导了
吉非替尼耐药的
EGFR突变(T790M)H1975细胞的癌
细胞死亡和凋亡。
SP101抑制了
磷酸化的
EGFR及其下游的Survivin蛋白,但相反地诱导了Ca
SPase 3的活化以诱导凋亡。此外,
SP101可以降低Oct4蛋白
水平,减少Survivin蛋白,但相反地在裸鼠体内异种移植的人类H1975肺肿瘤中引发活性Ca
SPase 3。